Philips combines SPECT camera with flat-panel x-ray
Philips Healthcare showcased at RSNA 2008 a hybrid SPECT/CT that incorporates a flat-panel x-ray system in place of a standard multislice CT. The FDA-cleared scanner, BrightView XCT, which debuted at the Society of Nuclear Medicine meeting in New Orleans, is built around the BrightView SPECT that Philips released commercially last year.
Philips Healthcare showcased at RSNA 2008 a hybrid SPECT/CT that incorporates a flat-panel x-ray system in place of a standard multislice CT. The FDA-cleared scanner, BrightView XCT, which debuted at the Society of Nuclear Medicine meeting in New Orleans, is built around the BrightView SPECT that Philips released commercially last year.
The novel combination is attuned specifically to the needs of specialists in nuclear medicine. The flat panel provides localization and attenuation correction at a lower cost than CT and with less technological complexity, so the system doesn't require special training for technologists, according to the company.
A side benefit is a two-thirds reduction in patient x-ray dose compared with MSCT. The XCT design is compact enough to allow siting in the same 12 x 15-foot room as the SPECT camera alone.
The system is scheduled to begin shipping next year at a price point somewhere between the company's $700,000 six-slice Precedence SPECT/CT and the $350,000 BrightView SPECT gamma camera. Beta testing is expected to begin in Q1 2009.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
